Results 71 to 80 of about 7,822 (173)

The Expanding Landscape of Microbiota Medicine: Indications, Therapeutic Modalities, and the Path Towards Integrative Microbiome‐Targeting Healthcare

Microbiota Medicine Research, Volume 1, Issue 2, Page 63-89, June 2026.
ABSTRACT The growing recognition of the microbiome’s role in human health has propelled the emergence of microbiota medicine—a new discipline integrating microbiology, multi‐omics, and clinical science. Advances in sequencing, data integration, and interventions such as fecal microbiota transplantation (FMT) have transitioned the field from ...
Min Dai, Yisha Lin, Renyou Gan, Xiaotao Shen, Shin Young Park, Sunjae Lee, Qi Su   +6 more
wiley   +1 more source

Targeting oncogenic fusion-driven NUT carcinoma with CRISPR-Cas9 genome editing

Molecular Therapy: Oncology
NUT carcinoma (NC) is a highly aggressive malignancy characterized by an oncogenic fusion gene incorporating the NUTM1 gene. To date, no established treatment options exist.
Maxim F. Carle, Tahereh Mohammadian Gol, Justin S. Antony, Alicia Roig-Merino, Mary E. Carter, Ulrich M. Lauer, Markus Mezger, Linus D. Kloker   +7 more
doaj   +1 more source

Theranostic Advancements in Brain Cancer: Promising Approaches for Emerging Therapy

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Strategies for improving intra‐arterial administration (A) and photodynamic therapy in brain cancer (B). Improving intra‐arterial (IA) administration and photodynamic therapy (PDT) for brain cancer involves enhancing tumor targeting and breaching the blood–brain barrier (BBB). Key strategies include super selective catheterization, using osmotic agents
Bipraban Khanra, Manoj Kumar Sarangi
wiley   +1 more source

Virotherapy in Head and Neck Cancer

Oral Oncology Reports
Head and neck cancer, comprising a diverse group of malignancies, presents significant challenges in terms of treatment efficacy and patient outcomes.
Zhan Wang
doaj   +1 more source

The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines

Molecular Therapy: Oncology
NUT carcinoma (NC) is a rare, yet aggressive disease (median survival of 6.5 months) of the young defined by a translocation of the nuclear protein in testis gene 1 (NUTM1).
Rieka C. Buchenau, Anne M. Schiller, Julia Beil, Susanne Berchtold, Andrea Schenk, Irina Smirnow, Mary E. Carter, Martin Schaller, Birgit Fehrenbacher, Anneli Vollert, Benjamin Schoeps, Rainer Kleemann, Ulrich M. Lauer, Linus D. Kloker   +13 more
doaj   +1 more source

Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus

Stem Cells International, 2017
Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors.
R. Moreno, L. A. Rojas, Felip Vilardell Villellas, Vanessa Cervera Soriano, J. García-Castro, C. A. Fajardo, R. Alemany   +6 more
doaj   +1 more source

Release the hounds: virotherapy with immunotherapy [PDF]

Blood, 2016
In this issue of Blood, Shen et al demonstrate that the vesicular stomatitis virus (VSV)-murine interferon β (IFNβ)-sodium iodide symporter (NIS) (VSV-mIFNβ-NIS) oncolytic virus has significant antileukemia activity, which is enhanced when combined with an anti-programmed death-ligand 1 (PD-L1) antibody.
openaire   +2 more sources

Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression

OncoImmunology, 2019
Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood.
Zhiwu Tan, Li Liu, Mei Sum Chiu, Ka-Wai Cheung, Chi Wing Yan, Zhe Yu, Boon Kiat Lee, Wan Liu, Kwan Man, Zhiwei Chen   +9 more
doaj   +1 more source

Patient-derived tumoroids and proteomic signatures: tools for early drug discovery

Frontiers in Immunology
Onco-virotherapy is an emergent treatment for cancer based on viral vectors. The therapeutic activity is based on two different mechanisms including tumor-specific oncolysis and immunostimulatory properties.
Hélène Lê, Hélène Lê, Jules Deforges, Pasquale Cutolo, Anissa Lamarque, Guoqiang Hua, Véronique Lindner, Véronique Lindner, Shreyansh Jain, Jean-Marc Balloul, Nadia Benkirane-Jessel, Eric Quéméneur   +11 more
doaj   +1 more source

Editorial: Oncolytic virotherapy

Frontiers in Molecular Biosciences, 2023
Ahmed Majeed Al-Shammari, Pier Paolo Piccaluga, Pier Paolo Piccaluga   +2 more
openaire   +3 more sources